WO2004103957A1 - Novel dithioketal - Google Patents
Novel dithioketal Download PDFInfo
- Publication number
- WO2004103957A1 WO2004103957A1 PCT/IN2003/000194 IN0300194W WO2004103957A1 WO 2004103957 A1 WO2004103957 A1 WO 2004103957A1 IN 0300194 W IN0300194 W IN 0300194W WO 2004103957 A1 WO2004103957 A1 WO 2004103957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- mol
- phenyl
- methyl
- Prior art date
Links
- 0 CC(C)C(C(C(C(c(cc1)ccc1F)(S*)S*)c1ccccc1)C(Nc1ccccc1)=O)=O Chemical compound CC(C)C(C(C(C(c(cc1)ccc1F)(S*)S*)c1ccccc1)C(Nc1ccccc1)=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
Definitions
- the present invention relates to a novel dithioketal compound of formula I and process for its preparation.
- US 5124482 and US 5216174 disclose manufacture and use of 4- Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzenebutane amide for preparation of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy -5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l- heptanoic acid.
- the present invention relates to novel compound of formula I.
- the present invention also relates to a process for preparation of compound of formula I.
- Ri and R are any suitable alkyl group or Ri and R 2 can join together to form any cyclic structure.
- the compound of formula I can be used to synthesize 4-Fluoro- ⁇ -[2-methyl-l- oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzenebutaneamide.
- the compound of formula I is an important intermediate for the preparation of drug molecules especially, HMG Co-A reductase inhibitors.
- HMG Co-A reductase inhibitors are useful as inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful as hypolipidemic or hypocholesterolemic agents.
- the compound of formula I of the present invention is new.
- FORMULA I The process of the present invention is also new, economical, and commercially feasible method for preparing intermediate used for the preparation of HMG CoA reductase inhibitors.
- the process of the present invention is outlined in Scheme I.
- the novel process comprises reaction of compound of formula II with compound of formula III.
- Ri and R 2 are any suitable alkyl group, preferably C 2 H 5 or Ri and R 2 can join together to form any cyclic structures, preferably - CH 2 _ CH -CH - ,
- reaction between compounds of formula II and III is carried 5 out in the presence of reagents selected from n-butyl lithium, NaH or LDA or any such suitable base.
- reaction can also be performed with above mentioned reagents in presence of Copper or Magnesium chloride or any suitable 10 Lewis acid to give compound of formula I in better yield.
- the compound of formula I can be further used for preparation of 4-Fluoro- ⁇ -[2-methyl-l-oxopropyl] ⁇ -oxo-N- ⁇ -diphenylbenzene butane amide which is key intermediate for manufacture of [R- (R*,R*)]-2-(4-Fluorophenyl)-B,D-Dihydroxy-5-(l-Methylethyl)-3- i5 Phenyl-4-[(Phenyl amino) Carbonyl]-lh-Pyrrole-l-Heptanoic Acid .
- Example 1 20 Preparation of l-[bis(ethylthio)methyl]-4- fluorobertzene: A solution of 4-fluorobenzaidehyde (25 g, 0.2 mol) in dry THF (250 ml) was stirred under nitrogen and ethanethiol (21.2 ml, 0.6 mol) and iodine (2.6 g, 0.01 « mol) were added. After stirring the reaction mixture for 45 minutes at room temperature, pH of the 25 mixture was adjusted to about 8.0 using 10% aqueous sodium hydroxide solution.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
A novel compound of formula (I) and a process for the preparation of compounds of formula (I): by reacting a compound of formula (II): Formula (III): with a compound of formula (III) where R1 and R2 are any suitable alkyl group, preferably C2H5 or R1 and R2 can join together to form any cyclic structure, preferably -CH2-Ch2-CH2-.
Description
Novel Dithioketal FIELD OF INVENTION
The present invention relates to a novel dithioketal compound of formula I and process for its preparation.
BACKGROUND OF INVENTION
US 5124482 and US 5216174 disclose manufacture and use of 4- Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzenebutane amide for preparation of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy -5-(l-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l- heptanoic acid. [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy -5-(l- methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lh-pyrrole-l- heptanoic acid is inhibitor of HMG CoA reductase and thus is used as antihypercholesterolemic agent. Hitherto unknown compound of the formula I
Formula I
Is an extremely useful novel intermediates for preparation 4-Fluoro-α- [2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzenebutaneamide.
SUMMARY OF THE INVENTION
The present invention relates to novel compound of formula I. The present invention also relates to a process for preparation of compound of formula I.
Formula I As mentioned earlier the compounds of formula I can be prepared by a novel process comprising, reaction of compound of formula II with compound of formula III.
Formula II
Formula III where Ri and R are any suitable alkyl group or Ri and R2 can join together to form any cyclic structure.
In the other embodiment of the invention, the compound of formula I can be used to synthesize 4-Fluoro-α-[2-methyl-l- oxopropyl]γ-oxo-N-β-diphenylbenzenebutaneamide.
DETAILED DESCRIPTION OF THE INVENTION
The compound of formula I is an important intermediate for the preparation of drug molecules especially, HMG Co-A reductase inhibitors. The HMG Co-A reductase inhibitors are useful as inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful as hypolipidemic or hypocholesterolemic agents.
The compound of formula I of the present invention is new.
FORMULA I
The process of the present invention is also new, economical, and commercially feasible method for preparing intermediate used for the preparation of HMG CoA reductase inhibitors. The process of the present invention is outlined in Scheme I.
The novel process comprises reaction of compound of formula II with compound of formula III.
Formula II
Formula III
where Ri and R2 are any suitable alkyl group, preferably C2H5 or Ri and R2 can join together to form any cyclic structures, preferably - CH2 _CH -CH - ,
The reaction between compounds of formula II and III is carried 5 out in the presence of reagents selected from n-butyl lithium, NaH or LDA or any such suitable base.
The reaction can also be performed with above mentioned reagents in presence of Copper or Magnesium chloride or any suitable 10 Lewis acid to give compound of formula I in better yield.
The compound of formula I can be further used for preparation of 4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo-N-β-diphenylbenzene butane amide which is key intermediate for manufacture of [R- (R*,R*)]-2-(4-Fluorophenyl)-B,D-Dihydroxy-5-(l-Methylethyl)-3- i5 Phenyl-4-[(Phenyl amino) Carbonyl]-lh-Pyrrole-l-Heptanoic Acid .
The following non-limiting examples illustrate the inventors' preferred method for preparing the compounds of the invention.
EXAMPLES
Example 1 20 Preparation of l-[bis(ethylthio)methyl]-4- fluorobertzene: A solution of 4-fluorobenzaidehyde (25 g, 0.2 mol) in dry THF (250 ml) was stirred under nitrogen and ethanethiol (21.2 ml, 0.6 mol) and iodine (2.6 g, 0.01 « mol) were added. After stirring the reaction mixture for 45 minutes at room temperature, pH of the 25 mixture was adjusted to about 8.0 using 10% aqueous sodium
hydroxide solution. The reaction mixture was extracted with ether (2 x 100 ml) and combined organic extract was washed with water (2 x 50 ml) brine (2 x 50 ml) and concentrated to obtain title compound. Yield: 20 g, 43.4%. Example 2
Preparation of 2-(4-fluorophenyl)-l,3-dithϊane: A solution of 4-fluorobenzaldehyde (20 g, 0.16 mol) in dry THF (200 ml) was stirred under nitrogen and 1,3-proanethiol (26 g, 0.24 mol) and iodine (2 g, 0.008 mol) were added. After stirring the reaction mixture for 2 h, at room temperature, pH of the mixture was adjusted to about 8.0 using 10% aqueous sodium hydroxide solution. The reaction mixture was extracted with ether (2 x 100 ml) and combined organic extract was washed with water (2 x 50 ml) brine (2 x 50 ml) and concentrated to obtain title compound. Yield: 28 g, 79%. Example 3
Preparation of 2-[2,2-bis-ethylsulphanyl-2-(4-fluoro- phenyl)-l-phenyl-ethyϊ]-4-methyl-3-oxo-pentanoic acid phenylamide: To a chilled solution of l-[bis(ethylthio)methyl]-4- fluorobenzene (5 g, 0.021 mol) in dry THF(50 ml), n-butyl lithium (18 ml, 0.021 mol) in hexane was added dropwise under nitrogen atmosphere, maintaining the temperature between -20° C and -25° C and stirred for 30 minutes at the same temperature. A solution of 2- isobutyryl-/V,3-diphenylacrylamide (6.3 g, 0.021 mol) in THF (20 ml) was added to the reaction mixture dropwise, maintaining the temperature between -20° C and -25° C and stirred for 30 minutes at the same temperature. After warming to room temperature, it was
further stirred for one hour. The reaction mixture was quenched with water (50 ml) and extracted with ethyl acetate (2 x 50 ml). Combined organic extract was washed with water (2 x 50 ml) brine (2 x 50 ml) and concentrated to obtain title compound.
5 Yield: 8.5 g, 77%. Example 4
Preparation of 2-[2,2-bis-ethylsulphanyl-2-(4~fIuoro- phenyI)-l-phenyl-ethyI]-4-methyI-3-oxo-pentanoic acid phenylamide: To a chilled mixture of l-[bis(ethylthio)methyl]-4- ιo fluorobenzene (5 g, 0.021 mol) and copper (II) chloride (0.15 g,
0.00011 mol) in dry THF(50 mL), n-butyl lithium (18 mL, 0.021 mol) in hexane was added dropwise under nitrogen atmosphere, maintaning the temperature between -20° C and -25° C and stirred for 30 minutes at the same temperature. A solution of 2-isobutyryl-/V,3- i5 diphenylacrylamide (6.3 g, 0.021 mol) in THF (20 mL) was added to the reaction mixture dropwise, maintaning the temperature between - 20° C and -25° C and stirred for 30 minutes at the same temperature. After warming to room temperature, it was further stirred for one hour. The reaction mixture was quenched with water (50 mL) and
20 extracted with ethyl acetate (2 x 50 mL). Combined organic extract was washed with water (2 x 50 mL) brine (2 x 50 mL) and concentrated to obtain title compound. Yield: 9.5 g, 86%. Example 5
25 Preparation of 2-{[2-(4-fluoro-phenyl)-[l,3]dithian-2- yl]-phenyl-methyl>-4-methyl-3-oxo-pentanoic acid phenylamide: To a chilled solution of 2-(4-fluorophenyl)-l,3-dithiane
(1 g, 0.005 mol) in dry THF (10 ml), n-butyl lithium (18 ml, 0.021 mol) in hexane was added dropwise under nitrogen atmosphere, maintaining the temperature between -20° C and -25° C and stirred for 30 minutes at the same temperature. A solution of 2-isobutyryl- /V,3-diphenylacrylamide (1.6 g, 0.0055 mol) in THF (10 ml) was added to the reaction mixture dropwise, maintaining the temperature between -20° C and -25° C and stirred for 30 minutes at the same temperature. After warming to room temperature, it was further stirred for one hour. The reaction mixture was quenched with water (50 ml) and extracted with ethyl acetate (2 x 25 ml). Combined organic extract was washed with water (2 x 25 ml) brine (2 x 25 ml) and concentrated to obtain title compound. Yield: 0.8 g, 54%. Example 6 Preparation of 2-{[2-(4-fluoro-phenyl)-[l,3]dϊthian-2- yl]-phenyl-methyl>-4-methyl-3-oxo-pentanoic acϊd phenylamide: To a chilled mixture of 2-(4-fluorophenyl)-l,3-dithiane (1 g, 0.005 mol) and magnesium chloride (250 mg, 0.00025 mol) in dry THF (10 mL), n-butyl lithium (18 mL, 0.021 mol) in hexane was added dropwise under nitrogen atmosphere, maintaning the temperature between -20° C and -25° C and stirred for 30 minutes at the same temperature. A solution of 2-isobutyryl-/V,3- diphenylacrylamide (1.6 g, 0.0055 mol) in THF (10 mL) was added to the reaction mixture dropwise, maintaning the temperature between - 20° C and -25° C and stirred for 30 minutes at the same temperature. After warming to room temperature, it was further stirred for one hour. The reaction mixture was quenched with water (50 mL) and
extracted with ethyl acetate (2 x 25 mL). Combined organic extract was washed with water (2 x 25 mL) brine (2 x 25 mL) and concentrated to obtain title compound. Yield: 2.0 g, 71%. Example 7
Preparation of 2-[2-(4-fluoro-phenyl-2-oxo-l-phenyl- ethyl]-4-methyl~3-oxo-pentanoic acid phenylamide: To a stirred solution of red mercury(II) oxide (4.13 g, 0.0190 mol) and boron trifluoride etherate (2.4 ml, 0.019 mol) in 15% aqueous THF (50 ml) a solution of 2-[2,2-bis-ethylsulphanyl-2-(4-fluoro-phenyl)-l- phenyl-ethyl]-4-methyl-3-oxo-pentanoic acid phenylamide (5 g, 0.0095 mol) in THF (20 ml) was added dropwise and stirred for 30 minutes. After adding diethyl ether (100 ml), the reaction mixture was filtered. The organic layer was washed with 10% sodium carbonate solution, brine and concentrated. Precipitated product was filtered. Yield: 2 g, 49%. Example 8
Preparation of 2-[2-(4-fluoro-phenyl-2-oxo-l-phenyl- ethyl]-4-methyϊ-3-oxo-pentanoic acid phenylamide: A solution of 2-{[2-(4-fluoro-phenyl)-[l,3]dithian-2-yl]-phenyl-methyl}-4-methyl- 3-oxo-pentanoic acid phenylamide (5g, 0.0098 mol), copper(II) chloride (2.65 g, 0.02 mol) and copper(II) oxide (3.1 g, 0.04 mol) in 995 aqueous acetone (50 ml) was refluxed for 1 h. The reaction mixture was filtered and concentrated. The residue was redissolved in diethyl ether (50 ml) and filtered again. The filtrate was concentrated and precipitated product was filtered. Yield: 2.2 g, 54%.
Scheme I:
Claims
1. A Compound of formula I
where Ri and R2 are any suitable alkyl group, preferably C2H5 or Ri and R2 can join together to form any cyclic structures, preferably -CH2-Ch2-CH2- .
2. A process for the preparation of compounds of formula I comprising reacting a compound of formula II with a compound of formula III to get compounds of formula
Formula II 
Formula III
where Ri and R2 are any suitable alkyl group, preferably C2H5 or Ri and R2 can join together to form any cyclic structures, preferably - CH2-Ch2-CH2- .
3. A process in claim 2, wherein the reaction between compounds of formula II and III is carried out in the presence of a base.
4. A process in claim 2, wherein the reaction between compounds of formula II and III is carried out in the presence of a base and a suitable Lewis acid.
5. A process in claim 3, wherein the base is selected one or more among n-butyi lithium, NaH or LDA.
6. A process in claim 4, wherein the Lewis acid is selected from salts of copper or magnesium.
7. A compound of formula I as in claim 1, wherein the compound is used for production of 4-Fluoro-α-[2-methyl-l-oxopropyl]γ-oxo- N-β-diphenylbenzenebutaneamide.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2003/000194 WO2004103957A1 (en) | 2003-05-22 | 2003-05-22 | Novel dithioketal |
| AU2003238680A AU2003238680A1 (en) | 2003-05-22 | 2003-05-22 | Novel dithioketal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2003/000194 WO2004103957A1 (en) | 2003-05-22 | 2003-05-22 | Novel dithioketal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004103957A1 true WO2004103957A1 (en) | 2004-12-02 |
Family
ID=33463009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2003/000194 WO2004103957A1 (en) | 2003-05-22 | 2003-05-22 | Novel dithioketal |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003238680A1 (en) |
| WO (1) | WO2004103957A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057859A3 (en) * | 2006-11-01 | 2008-12-31 | Bristol Myers Squibb Co | Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof |
| CN114195670A (en) * | 2021-12-31 | 2022-03-18 | 河南豫辰药业股份有限公司 | Refining method of atorvastatin mother nucleus M4 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| WO2003004457A2 (en) * | 2001-07-04 | 2003-01-16 | Ciba Specialty Chemicals Holding Inc. | Preparation process for atorvastatin and intermediates |
-
2003
- 2003-05-22 WO PCT/IN2003/000194 patent/WO2004103957A1/en active Application Filing
- 2003-05-22 AU AU2003238680A patent/AU2003238680A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| WO2003004457A2 (en) * | 2001-07-04 | 2003-01-16 | Ciba Specialty Chemicals Holding Inc. | Preparation process for atorvastatin and intermediates |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057859A3 (en) * | 2006-11-01 | 2008-12-31 | Bristol Myers Squibb Co | Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof |
| US8222247B2 (en) | 2006-11-01 | 2012-07-17 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof |
| CN114195670A (en) * | 2021-12-31 | 2022-03-18 | 河南豫辰药业股份有限公司 | Refining method of atorvastatin mother nucleus M4 |
| CN114195670B (en) * | 2021-12-31 | 2024-03-15 | 河南豫辰药业股份有限公司 | Refining method of atorvastatin mother nucleus M4 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003238680A1 (en) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2269515C2 (en) | Synthesis of atorvastatine and intermediate phenylboronate (variants) | |
| KR101808479B1 (en) | Method for producing phenylacetamide compound | |
| CZ283003B6 (en) | SYNTHESIS METHOD OF (4R-cis)-1,1-DIMETHYLETHYL-6-CYANOMETHYL-2,2- DIMETHYL-1,3-DIOXANE-4-ACETATE AND INTERMEDIATES FOR SUCH SYNTHESIS | |
| CZ285554B6 (en) | Process for preparing trans-6-[2-(substituted pyrrol-1-yl)alkyl]-pyran-2-one | |
| AU2003218994B2 (en) | Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives | |
| US7300953B2 (en) | Process for preparing nitrile compound, carboxylic acid compound or carboxylic acid ester compound | |
| US20090131683A1 (en) | Process for the preparation of atorvastatin and intermediates | |
| JP3845806B2 (en) | Synthesis method of α-substituted acrylic acid and use thereof | |
| US7235665B2 (en) | Process for the production of piperidine derivatives | |
| WO2004103957A1 (en) | Novel dithioketal | |
| KR100598079B1 (en) | Novel boronate esters | |
| FI120347B (en) | A novel process for the preparation of diisopinocamphampheylchloroborane and a process for reducing prochiral ketone | |
| WO2003004457A2 (en) | Preparation process for atorvastatin and intermediates | |
| US6586616B1 (en) | Process for preparing(R)-4-cyano-3-hydroxybutyric acid ester | |
| MX2007016049A (en) | Process for the preparation of 1-[cyano (4-hydroxyphenyl)methyl]c yclohexanol compounds. | |
| KR20080078127A (en) | Atorvastatin intermediates and method for producing the same | |
| JP4820965B2 (en) | Methods and intermediate compounds useful in the preparation of statins, particularly atorvastatin | |
| CA2278988A1 (en) | An efficient synthesis of furan sulfonamide compounds useful in the synthesis of new il-1 inhibitors | |
| WO2009084827A2 (en) | Synthetic intermediates, process for preparing pyrrolylheptanoic acid derivatives therefrom | |
| EP1426356B1 (en) | Intermediate compounds for the preparation of mirtazapine and the production methods thereof | |
| US5066825A (en) | Process for preparing a naphthalene derivative | |
| JPH05117263A (en) | Production of 3-amino-2-thiophenecarboxylic acid derivative | |
| US20050113607A1 (en) | Novel halo-substituted active methylene compounds | |
| JPH0649681B2 (en) | Process for producing 3-cyano-4-arylpyrrole | |
| US4551537A (en) | Synthesis of alpha-aminonitriles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 3108/CHENP/2005 Country of ref document: IN |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |